

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Applicant's representative, Cynthia Soroos, on May 8, 2008.

The application has been amended as follows:

In the claims:

In **claim 5**, replace the term --dolstatins-- with the term -- a dolstatin--

In **claim 25**, replace the last two lines with --Cyclosporin A, and a derivative of any of the foregoing.--

Replace **claim 28** with the following claim:

A compound selected from the group consisting of Suc- β Ala-Leu-Ala-Leu-Dox (Suc-(SEQ ID NO:38)-Dox), Suc- β Ala-Leu-Ala-Leu-Dnr (Suc-(SEQ ID NO:38)-Dnr) and Glutaryl- β Ala-Leu-Ala-Leu-Dox (Glutaryl-(SEQ ID NO:38)-Dox).

In **claim 37**, replace the term --dolstatins-- with the term -- a dolstatin--

Replace **claim 119** with the following claim:

The compound of claim 28 wherein the compound is Suc- β Ala-Leu-Ala-Leu-Dox (Suc-(SEQ ID NO:38)-Dox).

In **claim 135**, replace the last two lines with --Mephalan, Chloroquine, Cyclosporin A, and a derivative of any of the foregoing.--

The following is an examiner's statement of reasons for allowance: The closest prior art of record does not teach or suggest, alone or in combination, attaching a negatively charged protecting group at the N-terminus of the peptide or the attachment of the recited classes of therapeutic compounds. Furthermore, the above amendments are made to insert sequence identifiers with the sequences recited, remove the term 'analogs' and to correct 'dolstatins' to be consistent with other members of the Markush.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

In view of the amendments above, claims 2, 5, 13-16, 18-21, 25-28, 37, 118-120, 126, 130, 131, 135 and 136 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew D. Kosar whose telephone number is (571)272-0913. The examiner can normally be reached on Monday - Friday 08:00 - 16:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia J. Tsang can be reached on (571)272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Andrew D Kosar/
Primary Examiner, Art Unit 1654